Charlotte L. Zuur

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Elisa A. Rozeman, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · The Lancet Oncology · 2019 · 498 citations

Oncology, Medicine, Melanoma +6

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

Elisa A. Rozeman, Esmée P. Hoefsmit, Irene L. M. Reijers et al. · Nature Medicine · 2021 · 322 citations

Biomarker Analyses, Medicine, Melanoma +8

Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Irene L. M. Reijers, Alexander M. Menzies, Alexander C. J. van Akkooi et al. · Nature Medicine · 2022 · 322 citations · Full text

Surgical Oncology, Oncology, Prado Trial +10

Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman et al. · Nature Communications · 2021 · 317 citations · Full text

Concomitant radio- and fluorescence-guided sentinel lymph node biopsy in squamous cell carcinoma of the oral cavity using ICG-99mTc-nanocolloid

Nynke S. van den Berg, Oscar R. Brouwer, W. Martin C. Klop et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2012 · 171 citations

Engineering, Cancer Detection, Squamous Cell Carcinoma +10